Display options
Cite
Baranova A, Chandhoke V, Makarova AV, et al. In a search of a protective titer: Do we or do we not need to know?. Clin Transl Med. 2021;11(12):e668doi: 10.1002/ctm2.668.
Baranova, A., Chandhoke, V., Makarova, A. V., & Veytsman, B. (2021). In a search of a protective titer: Do we or do we not need to know?. Clinical and translational medicine, 11(12), e668. https://doi.org/10.1002/ctm2.668
Baranova, Ancha, et al. "In a search of a protective titer: Do we or do we not need to know?." Clinical and translational medicine vol. 11,12 (2021): e668. doi: https://doi.org/10.1002/ctm2.668
Baranova A, Chandhoke V, Makarova AV, Veytsman B. In a search of a protective titer: Do we or do we not need to know?. Clin Transl Med. 2021 Dec;11(12):e668. doi: 10.1002/ctm2.668. PMID: 34898055; PMCID: PMC8666578.
Copy Download .nbib Format: NLM
Share it on

Clin Transl Med. 2021 Dec;11(12):e668. doi: 10.1002/ctm2.668.

In a search of a protective titer: Do we or do we not need to know?.

Clinical and translational medicine

Ancha Baranova, Vikas Chandhoke, Alena V Makarova, Boris Veytsman

Affiliations

  1. School of System Biology, College of Science, George Mason University, Fairfax, Virginia, USA.
  2. Research Center for Medical Genetics RAMS, Moscow, Russia.
  3. Institute of Molecular Genetics, National Research Center, Kurchatov Institute, Moscow, Russia.

PMID: 34898055 PMCID: PMC8666578 DOI: 10.1002/ctm2.668

Abstract

The level of postvaccine protection depends on two factors: antibodies and T-cell responses. While the first one is relatively easily measured, the measuring of the second one is a difficult problem. The recent studies indicate that the first one may be a good proxy for the protection, at least for SARS-CoV-2. The massive data currently gathered by both researcher and citizen scientists may be pivotal in confirming this observation, and the collective body of evidence is growing daily. This leads to an acceptance of IgG antibody levels as an accessible biomarker of individual's protection. With enormous and immediate need for assessing patient condition at the point of care, quantitative antibody analysis remains the most effective and efficient way to assess the protection against the disease. Let us not discount importance of reference points in the turmoil of current pandemics.

© 2021 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.

Keywords: antibodies; biomarkers; covid-19; vaccine protection

References

  1. Nat Med. 2021 Nov;27(11):2032-2040 - PubMed
  2. mBio. 2021 Aug 31;12(4):e0150321 - PubMed
  3. Clin Infect Dis. 2021 Aug 10;: - PubMed
  4. Nat Immunol. 2021 May;22(5):620-626 - PubMed
  5. Clin Infect Dis. 2008 Aug 1;47(3):401-9 - PubMed
  6. Nat Med. 2021 Jul;27(7):1205-1211 - PubMed
  7. Pediatr Infect Dis J. 1995 Mar;14(3):203-9 - PubMed
  8. EBioMedicine. 2021 Aug;70:103539 - PubMed

Publication Types